FDA Meeting Types: Type A, B, and C Decoded

The problem: you’re scanning a biotech press release and you hit the line, “the company has completed a positive End-of-Phase 2 meeting with the FDA.” Your instinct is that approval odds just went up. It is a common instinct. Five years of trading FDA catalysts teaches the hard way that a “positive” meeting usually means the FDA agreed on what the trial will look like, not that the drug is going to work.

The solution: learn the three meeting types and the clock that drives them. Type A, Type B, and Type C meetings run on a 30, 60, and 75-day scheduling clock. The meeting type tells you exactly what the FDA agreed to, and the clock tells you how serious it is.

What the three meeting types actually are

The FDA sorts every formal meeting with a drug sponsor into three buckets, defined in the agency’s own guidance.

Type A: a meeting needed to get a stalled program moving again or to resolve a safety issue. These are the emergency meetings: dispute resolution after a Complete Response Letter, getting a clinical hold lifted, or responding to a special protocol assessment the FDA rejected. The FDA schedules Type A meetings fastest, within 30 days of the request.

Type B: the milestone meetings. Pre-IND, End-of-Phase 1, End-of-Phase 2, and pre-NDA or pre-BLA meetings all fall here. These are the checkpoints where the company and the FDA align on trial design before the next big step. The FDA schedules Type B meetings within 60 days.

Type C: the catch-all. Any meeting that isn’t a Type A or a Type B lands here. These cover narrower questions: a specific endpoint, a statistical analysis plan, a manufacturing detail. The FDA schedules Type C meetings within 75 days.

Here’s the part that takes years to internalize: the clock is the tell. Type A is the fastest meeting because it’s the trouble meeting. When the FDA commits to sitting down within 30 days, the program is stalled or the safety picture is bad. A Type A meeting in a press release is not good news. It’s the company asking the FDA to unblock a problem.

Step 1: Identify the meeting type

Read the press release for the specific phrase: “End-of-Phase 2 meeting,” “pre-NDA meeting,” “Type C meeting,” “Type A meeting.” Each one maps to a precise point on the drug development ladder.

If the phrase is vague, something like “completed a successful FDA meeting” with no type named, that’s a yellow flag. Companies name the meeting type when the news is clean. They get vague when it isn’t. The full ladder, from first meeting to approval decision, is mapped in the guide to how biotech drugs get FDA approved.

Step 2: Read the language, not the headline

This is where most investors get burned. Here’s what the standard phrases actually mean.

“Positive End-of-Phase 2 meeting” means the FDA agreed on the Phase 3 trial design: the endpoints, the patient population, the control arm. It does not mean the data is approvable, because there is no Phase 3 data yet. A positive EOP2 meeting raises the odds the Phase 3 will be accepted by the FDA, and that’s real de-risking. But it’s a design sign-off, not a vote on the drug.

“Positive pre-NDA meeting” means the FDA agreed the application is complete enough to file. That’s it. The FDA can still reject the drug after review. A positive pre-NDA meeting does not mean approval is a lock. The agency is saying “your paperwork is in order,” not “your drug works.”

There’s also a gap between the company’s version and the FDA’s version. After every formal meeting, the FDA sends the sponsor official minutes within about 30 days. Those minutes are the FDA’s record of what was agreed. The press release is the company’s record, and companies round up. If a meeting was “positive” in the press release, wait for the minutes before you bet on it.

One more phrase to watch: “major amendment.” When a company submits new data mid-review that the FDA judges substantial, the agency reclassifies it as a major amendment and extends the PDUFA date, usually by three months. It’s administrative, not scientific, but it costs three months. Savara hit exactly this on MOLBREEVI: the FDA pushed the PDUFA from August 22 to November 22, 2026, after Savara’s responses to information requests were deemed a major amendment. The stock dropped about 13%, and the delay said nothing about the underlying data, which was clean. Read the full case in the Savara MOLBREEVI analysis.

Step 3: Map the meeting to approval probability

Not all meetings move the needle the same amount.

Pre-IND (Type B): the earliest checkpoint. Low signal. The company hasn’t dosed a patient yet.

End-of-Phase 2 (Type B): the biggest de-risking event before a filing. If the FDA signs off on the Phase 3 design, the odds the Phase 3 will be accepted by the agency go up materially. This is the meeting worth caring about.

Pre-NDA / pre-BLA (Type B): the last check before filing. A positive one means the application is file-ready, not that it’s approvable.

Type C: housekeeping. Rarely a stock-moving event on its own.

Step 4: Stack the meetings against the designations

A single meeting is a data point. A pattern of meetings plus designations is a signal. When a company has multiple FDA meetings, a Breakthrough Therapy designation, and Priority Review, that’s regulatory alignment: the agency is engaged, moving fast, and not finding reasons to slow the program down. Cogent Biosciences’ bezuclastinib for systemic mastocytosis is the live example: Breakthrough Therapy plus Priority Review plus a string of FDA meetings ahead of its November 30 PDUFA date.

The opposite is also true. A company that went quiet after its last meeting, or that keeps scheduling new meetings to “align” on things it should have aligned on already, is telling you the program is wobbling.

Common mistakes

Reading “positive meeting” as approval. A positive End-of-Phase 2 meeting means the design is set, not the drug is good. If you buy on that headline alone, you’re paying for approval odds that don’t exist yet.

Ignoring the meeting type. A Type A meeting is a distress signal. A Type C meeting is routine. Treating them the same is how you get caught holding into a dispute-resolution meeting that tanks the stock.

Confusing pre-NDA with approvability. “Positive pre-NDA meeting” sounds like the finish line. It’s the starting line of the review. The CRL risk is still live, as the guide to Complete Response Letters explains.

Over-reading “major amendment.” A three-month PDUFA extension is a delay, not a rejection. But it does push your catalyst out a quarter, and if you sized for a date that’s now wrong, you’re holding more binary risk than you planned.

Final checklist

When a biotech announces an FDA meeting, answer these five questions before you trade it:

1. What type of meeting was it: Type A, B, or C?
2. What did the FDA actually agree to: trial design, endpoints, or just filing readiness?
3. Is there a “major amendment” or a date change hiding in the fine print?
4. Which designations (Breakthrough Therapy, Priority Review) ride alongside the meeting?
5. Would the FDA’s minutes say the same thing the press release said?

Once the meeting is behind you, the next binary event is the AdCom or the PDUFA itself. The full meeting ladder is spelled out in the FDA’s formal meetings guidance, and the upcoming meeting calendar is on BioPharmCatalyst. Between the two, you can see every checkpoint a drug has to clear, and what each one actually tells you about the odds.